Pharmacy Grand Rounds

Escaping Vaping: Where We Are and Where Do We Go From Here?

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)
MN-RO-AL-MN-459-MAYO LH

Interactive Video Conference Room(s): 
MN-RO-GO-19-101 BARRETTE LH

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

In the summer of 2019, there was a sharp increase in the number of emergency department visits for patients presenting with concerns of electronic-cigarette vaping product use-associated lung injury (EVALI). According to the Centers for Disease Control and Prevention, a total of 2,561 patients have been hospitalized for EVALI with 55 deaths in the United States and its territories. These cases have since been on the decline; however, EVALI has continued to have expansive coverage in the media. This presentation will review the current available information regarding the outbreak of EVALI, focusing on epidemiology, mechanisms of toxicity, and current options for treatment.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Discuss epidemiological data for EVALI
2. Recognize agents of importance and their mechanisms of toxicity in EVALI
3. Recall current options for treatment of EVALI

Session Announcement

Session Slides

FACULTY INFORMATION

Nicole L. Hlavacek, PharmD
PGY2 Emergency Medicine Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Nicole received a Doctor of Pharmacy degree from the University of Wyoming in Laramie, WY with subsequent completion of PGY1 training at UMass Memorial Medical Center in Worcester, MA. She is a current PGY2 Emergency Medicine Pharmacy Resident at Mayo Clinic Hospital-Rochester with practice interests in emergency medicine, toxicology, and infectious diseases.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Nicole L. Hlavacek, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Corticosteroids

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS